FDA Approves Varubi for Chemo-Induced Nausea, Vomiting

Share this content:
FDA Approves Varubi for Chemo-Induced Nausea, Vomiting
FDA Approves Varubi for Chemo-Induced Nausea, Vomiting

WEDNESDAY, Sept. 2, 2015 (HealthDay News) -- Varubi (rolapitant) has been approved by the U.S. Food and Drug Administration to prevent delayed phase chemotherapy-induced nausea and vomiting.

Varubi, a substance P/neurokinin-1 receptor antagonist, was evaluated in three clinical trials involving 2,800 participants. The drug was administered in combination with granisetron and dexamethasone. Patients taking Varubi reported a greater reduction in vomiting and use of rescue medication for nausea and vomiting, compared to those receiving a control therapy. The most common side effects included neutropenia, hiccups, loss of appetite, and dizziness.

The FDA said Varubi should not be taken by people who are taking the drug thioridazine, as the two drugs can interact to increase the amount of thioridazine in the blood, leading to abnormal heart rhythm.

"Chemotherapy-induced nausea and vomiting remains a major issue that can disrupt patients' lives and sometimes their therapy," Amy Egan, M.D., M.P.H., deputy director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said in a statement. "Today's approval provides cancer patients with another treatment option for the prevention of the delayed phase of nausea and vomiting caused by chemotherapy."

Varubi is marketed by Tesaro Inc., based in Waltham, Mass.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »